[Intraperitoneal administration of interferon gamma. An efficient adjuvant to the chemotherapy of ovarian cancers. Apropos of an European study of 108 patients].
One hundred and eight patients with residual epithelial ovarian cancer at second laparotomy, after first line plastine-based chemotherapy were treated with intraperitoneal rHU-interferon-gamma at a dose of 20 x 10(6) U/m2, twice a week for 3-4 months. 86% of the patients had residual macroscopic tumors and 33% bulky tumors (> 2 cm). From the 99 evaluable patients, 62 had an evaluative third laparotomy and nine additional patients a laparotomy. Complete pathologic and global response rates to interferon-gamma were 23 and 32% respectively. Age and tumor size were independently correlated with treatment response. Patients (n = 41) under the age of 60 with a tumor size less than 2 cm had a complete and global response rate of 42 and 54% respectively. Interferon-gamma was equally effective in chemo-resistant and chemosensitive tumors. Median duration of response was 21 months and median survival of responder patients was 86% at 2 years. In multivariate analysis, response to interferon-gamma was the most prominent prognostic factor of this population of patients with residual ovarian cancer.
Pujade-Lauraine
E
E
Hôtel-Dieu, Paris, France.
Guastella
J P
JP
Colombo
N
N
François
E
E
Fumoleau
P
P
Monnier
A
A
Nooy
M A
MA
Mignot
L
L
Bugat
R
R
Oliviera
C M
CM
D000328:Adult; D000368:Aged; D017024:Chemotherapy, Adjuvant; D004305:Dose-Response Relationship, Drug; D005060:Europe; D005260:Female; D006801:Humans; D007274:Injections, Intraperitoneal; D007371:Interferon-gamma / Q000008:administration & dosage / Q000627:therapeutic use*; D007813:Laparotomy; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000473:pathology / Q000628:therapy*; D011379:Prognosis; D012086:Reoperation; D016896:Treatment Outcome
D007371:Interferon-gamma
Interféron-gamma par voie intrapéritonéale. Un complément efficace de la chimiothérapie des cancers de l'ovaire. A propos d'une étude européenne de 108 patientes.